questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 1, 1996.

A. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. R. Banking Limited Partnership, and BancFirst Corporation, both of Oklahoma City, Oklahoma; to acquire 26.75 percent of the voting shares of Peoples State Bank, Tulsa, Oklahoma.

B. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. GB Bancorporation, San Diego, California; to acquire 24.99 percent of the voting shares of Pacific Commerce Bank, Chula Vista, California, and Rancho Vista National Bank, Vista, California.

2. Pierce County Bancorp, Tacoma, Washington; to become a bank holding company by acquiring 100 percent of the voting shares of Pierce Commercial Bank, Tacoma, Washington (in organization).

Board of Governors of the Federal Reserve System, October 3, 1996.

Jennifer J. Johnson

Deputy Secretary of the Board

[FR Doc. 96–25870 Filed 10–8–96; 8:45 am]

BILLING CODE 6210–01–F

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 23, 1996.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Comerica Incorporated, Detroit, Michigan; to acquire 26 percent of Bankers Motor Acceptance Corporation, Newport Beach, California, and thereby engage in subprime indirect automobile lending, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

2. Bank of Montreal, Montreal, Canada, and Bankmont Financial Corp., New York, New York; to engage *de novo* through their subsidiary, Nesbitt Burns Securities, Inc., New York, New York, in full service brokerage activities through offices in Canada, pursuant to § 225.25(b)(15) of the Board's Regulation Y.

B. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. First National of Nebraska, Inc., and First National of Colorado, Inc., both of Omaha, Nebraska; to engage *de novo* through their subsidiary, Professional Career Services, Inc., Omaha, Nebraska, in the provision of career counseling services to affiliated and unaffiliated financial organizations; individuals seeking employment at banks and other financial organizations; and individuals seeking financial positions at any company. See *Comerica, Inc.* 80 Fed. Res. Bull. 51 (1994).

2. R. Banking Limited Partnership and BancFirst Corporation, both of Oklahoma City, Oklahoma; to engage *de novo* through BancFirst Corporation, Oklahoma City, Oklahoma, in general lending activities, including the making and servicing of loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, October 3, 1996.

Jennifer J. Johnson

Deputy Secretary of the Board

[FR Doc. 96–25871 Filed 10–8–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Hanford Thyroid Morbidity Study Advisory Committee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Hanford Thyroid Morbidity Study Advisory Committee.

Time and Date: 8 a.m.–5 p.m., October 25, 1996.

Place: Terrance Garden Buckhead, 3405 Lenox Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 30 people.

Purpose: This committee is charged with providing advice and guidance to the Director, CDC, regarding the scientific merit and direction of the Hanford Thyroid Morbidity Study. The Committee will review development of the study protocol and recommend changes of scientific merit to CDC and advise on the conduct of a full-scale epidemiologic study using the approval protocol. During the conduct of the full-scale epidemiologic study, the Committee will advise the CDC on the design and conduct of the study and analysis of the results.

Matters to be Discussed: The Committee will discuss the progress and updates of the status of various components of the Hanford Thyroid Disease Study being conducted by the Fred Hutchison Cancer Research Center. Agenda items will include the National Center for Environmental Health (NCEH) activities on the progress of current studies, and public involvement activities.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Nadine Dickerson, Program Analyst, Radiation Studies Branch, Division of

Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F–35), Atlanta, Georgia 30341–3724, telephone 770/488–7040.

Dated: October 2, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 96–25874 Filed 10–8–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 96M–0356]

American Medical Systems, Inc.; Premarket Approval of UroLume™ Endourethral Prosthesis

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by American Medical Systems, Inc., Minnetonka, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the UroLume™ Endourethral Prosthesis. After reviewing the recommendation of the Gastroenterology and Urology Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of May 6, 1996, of the approval of the application.

DATES: Petitions for administrative review by November 8, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James P. Seiler, Center for Devices and Radiological Health (HFZ–470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–1195.

SUPPLEMENTARY INFORMATION: On June 14, 1993, American Medical Systems, Inc., Minnetonka, MN 55343, submitted to CDRH an application for premarket approval of the UroLume™ Endourethral Prosthesis. The device is intended for use in men to relieve urinary obstruction secondary to recurrent benign bulbar urethral strictures less than 3 centimeters in length located distal to the external sphincter and proximal to the bulbar scrotal junction. The UroLume™ Endourethral Prosthesis is not intended as an initial treatment for bulbar urethral strictures nor for the treatment of strictures outside the bulbar urethra. The UroLume™ Endourethral Prosthesis is an alternative treatment for the patient in whom previous treatment methods (e.g., dilation, urethrotomy, or urethroplasty) have been unsuccessful (i.e., treatment was not effective initially in relieving stricture disease, or there has been recurrence of stricture formation necessitating further treatment).

On January 20, 1995, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On May 6, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before November 8, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: September 20, 1996.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 96–25877 Filed 10–8–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96M–0358]

EDAP Technomed Group (U.S.A.), Inc.; Premarket Approval of Prostatron™

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by the EDAP Technomed Group (U.S.A), Inc., Cambridge, MA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the Prostatron™. After reviewing the recommendation of the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of May 3, 1996, of the approval of the application.

DATES: Petitions for administrative review by November 8, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: John H. Baxley, Center for Devices and Radiological Health (HFZ–470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2194.

SUPPLEMENTARY INFORMATION: On April 17, 1995, the EDAP Technomed Group